Levetiracetam Injection
Product Images NDC 43598-757

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43598-757). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000carton.jpg (1000carton)

This is a description for Levetiracetam in 0.75% Sodium Chloride Injection for Intravenous Infusion Only, produced by novaplus. The rest of the text contains errors and is not readable.*

FDA Label Image

1500 Carton.jpg (1500carton)

This is a description of a medication called Levetiracetam in 0.54% Sodium Chloride Injection, with a concentration of 1,500 mg/100 mL (15 mg/m). It is intended for intravenous infusion only and is produced by Novaplus.*

FDA Label Image

500carton.jpg (500caton)

This appears to be a label for a medication called Levetiracetam that is mixed with Sodium Chloride Injection for infusion through veins at a specific dosage. It is recommended for intravenous use only. There is also mention of dosage bags made by NovaPlus.*

FDA Label Image

Figure1 (Figure1)

This appears to be a chart or table displaying percentages and statistical significance. It is related to the administration of two drugs, Levtiacram and Levetracetam, at different dosages, and their impact on an unspecified number of patients. However, it is difficult to provide additional context or understanding without further information or the ability to read the text more accurately.*

FDA Label Image

Figure2 (Figure2)

The text describes the results of a study comparing the effectiveness of a placebo versus two different doses of a medication called Levetiracetam in the treatment of a medical condition. The number of patients in each group is provided, as well as the dosage of the medication being taken. The text notes that the medication was found to be statistically significant in its effectiveness when compared with the placebo.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This is a summary of a statistical analysis involving two groups of patients given a placebo and Lovetiracatam. The first group showed a success rate of 72.2%, while the second group achieved a success rate of 45.2%. The number of patients involved was three. The analysis indicated Lovetiracatam had a statistically significant effect compared to the placebo.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.